Cistron Biotechnology(CIST)$.30 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rudy Saucillo who wrote (1252)	7/7/1998 5:06:00 PM
From: Zvi Yammer	Read Replies (1) of 2742

Rudy; And to continue. Cistron will have 300,000 per year to continue the research. Plus the 1.3 million This is not as a NEW drug trial, it is as an adjuvant. Which means the IL-1 is added to the process of mfgr. the drug. I do not believe that clinical trials will be as drawn out as would be for a true New Drug Application. Basically, I would assume that based on the Novavax trials the IL1 has a basis for minimal toxicity. RP should go directly to human trials after an agreed upon flu "cocktail" has been stirred up. What about Novavax. Picked up a few since I think this will be related.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next